|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM266586457 |
| 003 |
DE-627 |
| 005 |
20231224214848.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2017 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2016.11.008
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0888.xml
|
| 035 |
|
|
|a (DE-627)NLM266586457
|
| 035 |
|
|
|a (NLM)27890706
|
| 035 |
|
|
|a (PII)S1521-6616(16)30313-8
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Mao-Draayer, Yang
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The sphingosine-1-phosphate receptor
|b A novel therapeutic target for multiple sclerosis and other autoimmune diseases
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 05.06.2017
|
| 500 |
|
|
|a Date Revised 22.08.2019
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2016 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Multiple sclerosis (MS) is a prototype autoimmune disease of the central nervous system (CNS). Currently, there is no drug that provides a cure for MS. To date, all immunotherapeutic drugs target relapsing remitting MS (RR-MS); it remains a daunting medical challenge in MS to develop therapy for secondary progressive MS (SP-MS). Since the approval of the non-selective sphingosine-1-phosphate (S1P) receptor modulator FTY720 (fingolimod [Gilenya®]) for RR-MS in 2010, there have been many emerging studies with various selective S1P receptor modulators in other autoimmune conditions. In this article, we will review how S1P receptor may be a promising therapeutic target for SP-MS and other autoimmune diseases such as psoriasis, polymyositis and lupus
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Lysophospholipids
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Lysosphingolipid
|2 NLM
|
| 650 |
|
7 |
|a sphingosine 1-phosphate
|2 NLM
|
| 650 |
|
7 |
|a 26993-30-6
|2 NLM
|
| 650 |
|
7 |
|a Sphingosine
|2 NLM
|
| 650 |
|
7 |
|a NGZ37HRE42
|2 NLM
|
| 700 |
1 |
|
|a Sarazin, Jeffrey
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fox, David
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Schiopu, Elena
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 175(2017) vom: 15. Feb., Seite 10-15
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:175
|g year:2017
|g day:15
|g month:02
|g pages:10-15
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2016.11.008
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 175
|j 2017
|b 15
|c 02
|h 10-15
|